Krystal Biotech updates 2026 non-GAAP R&D and SG&A expense guidance to $155 million-$165 million

Bitget2026/11/02 19:48

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Krystal Biotech updated full-year 2026 non-GAAP research and development and selling, general and administrative expense guidance to $155 million–$165 million.
Third-quarter net product revenue reached $127.3 million, compared with $97.8 million a year earlier.
Net income fell to $63.1 million from $79.4 million a year earlier.
A $400 million share repurchase program is being initiated; cash and investments totaled $1.2 billion as of September 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Krystal Biotech Inc. published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Krystal Biotech updates 2026 non-GAAP R&D and SG&A expense guidance to $155 million-$165 million

You may also like

Crypto prices